SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Martin Posgay who wrote (986)3/27/1999 8:22:00 AM
From: vestor   of 1837
 
Some interesting bits of news:

G. Gordon Liddy discussed the benefits of Cenestin and had a negative slant on Premarin. A little free press..

I wonder how many investors are aware of the Tamoxifin submission before the FDA. I have heard that this too is a block buster if approved.

I am being told that one of the dosages permitted of Cenestin is not available with Premain and that dosage is highly desireable by doctors... Can anyone confirm ?

Does anyone know of the financial impact to the companys bottom line for the two other drug approvals the week before ?

There are also three other ANDA's well along in the FDA pipeline. Does anyone know what they are and their impact ?

Given recent events and in consideration of upcoming events this company is not an $11. stock. Perhaps we may touch upon $10. soon as momentum players take profits. Are there any TA people with thoughts as to a good buyin price ?

When considering upside potential vs downside risk it seems it is reasonable to accmulate shares at these levels....

IMHO.....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext